2 months ago
2
Generic drugmaker Lupin has received U.S. Food and Drug Administration (USFDA) tentative support for Sugammadex injection.
The USFDA has tentatively approved Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vial arsenic bioequivalent to Merck’s Bridion Injection, it said connected Tuesday (March 31, 2026).
The cause is indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide successful adults and pediatric patients aged 2 years and older undergoing surgery, the institution said.
